ArticleAntimicrobial agents and chemotherapy2007
Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 1 synthesis or guideline pooled it, 176 citations in OpenAlex.
- Prioritization of Critical Factors for Surveillance of the Dissemination of Antibiotic Resistance inInternational journal of molecular sciences · 2023Pooled it
- Adverse Impact of Gamma-Polyglutamic Acid on the Antimicrobial Efficacy of Cefiderocol and Nanosilver Against Gram-NegativePharmaceutics · 2026Article
- Regulation, structure, and activity of theAntimicrobial agents and chemotherapy · 2025Review
- Resistome Signature and Antibiotic Resistance Mechanisms in Rhizospheric Soil Bacteriomes of Mecca Region, Saudi Arabia: Insights into Impact on Human Health.Life (Basel, Switzerland) · 2024Article
- Changes in the expression of mexB, mexY, and oprD in clinical Pseudomonas aeruginosa isolates.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2024Article
- Rocket-miR, a translational launchpad for miRNA-based antimicrobial drug development.mSystems · 2023Article
- Molecular basis of the phenotypic variants arising from aMicrobial genomics · 2023Article
- "Two Is Better Than One": The Multifactorial Nature of Phage-Antibiotic Combinatorial Treatments Against ESKAPE-Induced Infections.PHAGE (New Rochelle, N.Y.) · 2023Review
- Comparative Genomic Analysis of Multi-Drug ResistantMicroorganisms · 2023Article
- Mechanisms of Antibiotic and Biocide Resistance That Contribute toBiomedicines · 2023Review
- Antimicrobial and Antibiofilm Effect of Bacteriocin-ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Evidence-Based Treatment ofAntibiotics (Basel, Switzerland) · 2023Review
- Evaluation and analysis of multidrug resistance- and hypervirulence-associated genes in carbapenem-resistantFrontiers in microbiology · 2023Article
- Class C β-Lactamases: Molecular Characteristics.Clinical microbiology reviews · 2022Review
- Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa.Infectious diseases and therapy · 2022Review
- Mutators Enhance Adaptive Micro-Evolution in Pathogenic Microbes.Microorganisms · 2022Review
- Potential Therapeutic Targets for Combination Antibody Therapy againstAntibiotics (Basel, Switzerland) · 2021Review
- Antimicrobial Resistance and Inorganic Nanoparticles.International journal of molecular sciences · 2021Review
- Functionalized Antimicrobial Nanofibers: Design Criteria and Recent Advances.Journal of functional biomaterials · 2021Review
- Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, we analyzed the mechanisms of multiresistance for 22 clinical multiresistant and clonally different Pseudomonas aeruginosa strains from Germany. Twelve and 10 strains originated from cystic fibrosis (CF) and non-CF patients, respectively. Overproduction of the efflux systems MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM was studied. Furthermore, loss of OprD, alterations in type II topoisomerases, AmpC overproduction, and the presence of 25 acquired resistance determinants were investigated. The presence of a hypermutation phenotype was also taken into account. Besides modifications in GyrA (91%), the most frequent mechanisms of resistance were MexXY-OprM overproduction (82%), OprD loss (82%), and AmpC overproduction (73%). Clear differences between strains from CF and non-CF patients were found: numerous genes coding for aminoglycoside-modifying enzymes and located, partially in combination with beta-lactamase genes, in class 1 integrons were found only in strains from non-CF patients. Furthermore, multiple modifications in type II topoisomerases conferring high quinolone resistance levels and overexpression of MexAB-OprM were exclusively detected in multiresistant strains from non-CF patients. Correlations of the detected phenotypes and resistance mechanisms revealed a great impact of efflux pump overproduction on multiresistance in P. aeruginosa. Confirming previous studies, we found that additional, unknown chromosomally mediated resistance mechanisms remain to be determined. In our study, 11 out of 12 strains and 3 out of 10 strains from CF patients and non-CF patients, respectively, were hypermutable. This extremely high proportion of mutator strains should be taken into consideration for the treatment of multiresistant P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.